CA Market News
2週前
Cannabix Expands BreathLogix Alcohol Screening Technology into Mining, Municipal and Aviation Sectors in AustraliaMay 29, 2026 9:07 AM
InvestorsHub NewsWire
Cannabix Expands BreathLogix Alcohol Screening Technology into Mining, Municipal and Aviation Sectors in Australia Vancouver, British Columbia, May 29, 2026 -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (Frankfurt: 8CT) (the "Company or Cannabix") developer of marijuana and alcohol breath devices is pleased to announce the deployment of its BreathLogix alcohol screening technology with mining, municipal, and aviation clients in Australia. The deployments have been made under the Company's exclusive distribution partner in Australia, Breathalyser Sales & Service Pty Ltd.
These recent BreathLogix deployments mark an important step in Cannabix's strategy to penetrate high-value safety-critical sectors, where there is increasing demand for automated, reliable, and scalable alcohol screening solutions. These new deployments demonstrate adoption of BreathLogix as organizations seek to enhance workplace safety, reduce risk, and strengthen compliance programs. Furthermore, these installations highlight the system's ability to integrate into daily operational workflows across diverse industries.
BreathLogix (Figure 1 and 2) is an automated, unmanned alcohol screening system designed to deliver fast, consistent, and scalable testing without the need for dedicated administration personnel.
Figure 1. BreathLogix Alcohol device available with contactless and straw modes for rapid workplace pre-accessalcohol screening
In mining environments, BreathLogix is used for pre-shift and site access screening, helping operators ensure workers entering remote, high-risk sites are fit for duty and compliant with strict safety protocols.In municipal settings, the system supports fleet, public works, and safety-sensitive roles, enabling routine and random testing to reduce liability and enhance public safety oversight.In aviation operations, BreathLogix has been deployed for pre-duty screening of safety-sensitive personnel, such as ground crew, pilots and other operational staff, supporting compliance with strict zero-tolerance alcohol policies.
BreathLogix is designed for rapid, automated, and unmanned alcohol screening, making it particularly well-suited for industries where traditional testing methods can be time-consuming, resource-intensive, or difficult to enforce consistently. The system addresses a critical safety gap by enabling frequent, consistent testing without the need for dedicated personnel.The BreathLogix device rapidly screens for alcohol using a breath sample while simultaneously capturing a photograph of the user to support identity verification. The system provides precise Blood Alcohol Content (BAC / BrAC) readings on-screen and delivers real-time alerts via SMS and email to designated supervisors when positive results are detected—enabling immediate intervention to help prevent accidents, equipment damage, and workplace incidents.
Figure 2. BreathLogix Alcohol Screening Devices by Cannabix Technologies Inc.
All test data is securely logged and managed through the Company's BreathLogix Connect cloud-based platform, giving organizations full visibility into testing activity, compliance tracking, and reporting across multiple locations. BreathLogix can be integrated with access control systems including doors, turnstiles, gates, facial recognition, fingerprint readers, and vehicle fleet management systems, allowing for pre-access alcohol screening as part of standard operational workflows.
The platform supports a wide range of testing protocols, including:
Pre-shift and start-of-day testingRandom and mandated testingPre-employment screeningReturn-to-work assessmentsPost-incident investigations
These capabilities enable organizations to implement comprehensive alcohol safety programs that are both scalable and enforceable across distributed worksites.
We seek Safe Harbor. On behalf of the Board of Directors
"Rav Mlait"
CEOCannabix Technologies Inc.
For further information, contact the Company at info@cannabixtechnologies.com The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.
Cautionary Statement Regarding Forward-Looking Statements
This news release contains certain "forward-looking statements" within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as "anticipates," "plan," "continue," "expect," "project," "intend," "believe," "anticipate," "estimate," "may," "will," "potential," "proposed," "positioned" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements in this news release include, but are not limited to, statements relating to: certification of devices, acceptance of devices by international regulators, the achievement of any or all of the goals and aims of the distribution and sales agreement with any third-party companies; positive developments with contract manufacturers; the completion of pre-validation or validation testing; final development of a commercial or prototype product(s); the successful trial or pilot of company technologies; the commercialization of the Company's products; the negotiation and potential entry into additional agreements with distributors and or contract manufacturers; and the completion of future financings. There are numerous risks and uncertainties that could cause actual results and the Company's plans and objectives to differ materially from those expressed in the forward-looking information. Important factors that could cause actual results to differ materially from those expressed in the forward-looking information include (but are note limited to): adverse market conditions; risks regarding protection of proprietary technology; the ability of the Company to complete future financings; the ability of the Company to develop and market its future product; risks regarding government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition; that the Company's development of cannabis and alcohol breathalyzer technologies will provide any benefit to the Company; there is no assurance that any proposed new products will be built, will be successful in beta testing or clinical trials; there is no assurance that the Company will enter into any partnerships to advance any of its corporate initiatives or technologies; there is no assurance that any "patent pending" or "provisional patents" technologies licensed by the Company or owned by the Company will receive patent status by regulatory authorities; the Company is not currently selling breathalyzers and there is no assurance that the Company ever will; and other factors beyond the control of the Company. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements. Original: Cannabix Expands BreathLogix Alcohol Screening Technology into Mining, Municipal and Aviation Sectors in Australia
CA Market News
1月前
Cannabix Marijuana Breath Test Achieves Major Milestone: Breath Collection Unit Secures UL and CSA CertificationsMay 13, 2026 9:01 AM
InvestorsHub NewsWire
Cannabix Marijuana Breath Test Achieves Major Milestone: Breath Collection Unit Secures UL and CSA CertificationsVancouver, British Columbia, May 13, 2026 - Cannabix Technologies Inc. (CSE:BLO) (OTCID:BLOZF) (Frankfurt: 8CT) (the "Company or Cannabix") is pleased to announce that its portable Breath Collection Unit (BCU), a core component of the Company's Marijuana Breath Test (MBT), has successfully achieved Underwriters Laboratories (UL) and Canadian Standards Association (CSA) electrical safety certifications. The BCU along with Cannabix's proprietary Breath Cartridges are core hardware products of the MBT system (Figures 1 and 2).The Cannabix BCU has been certified to UL 61010-1 (United States) and CSA 61010-1-12 (Canadian) standards which are recognized North American safety standards that confirm a device is safe and suitable for professional, industrial, and regulated use. Testing and certification were completed at an independent ISO/IEC 17025 accredited laboratory recognized in both Canada and the United States for electrical safety evaluations.UL and CSA certifications are widely recognized top tier safety standards for electrical equipment used in the marketplace. Achieving certification under both safety standards represents an important regulatory, technical and commercial milestone for Cannabix as it advances its marijuana breath testing technology toward broader deployment.
These certifications will help:
Facilitate adoption by workplace safety, industrial, law enforcement and government customers that require UL and CSA compliance as a condition of procurement. Certification positions the BCU to be considered for formal tender processes and approved vendor lists that were previously inaccessible without it.Support commercialization efforts in both United States and Canada, reducing regulatory friction for pilot programs and salesDemonstrate product safety, reliability, and manufacturing quality, enhancing confidence among prospective partners, customers, and regulatorsEnable smoother integration into safety-critical and regulated environments
Figure 1. Cannabix Marijuana Breath Test hardware including Breath Collection Unit (BCU) and Breath Cartridge (BC) technologies.
The Cannabix BCU is designed to capture breath samples for laboratory analysis. Successfully meeting UL and CSA safety requirements validates the Company's engineering and design approach and aligns with its strategy to build regulatory-ready technology for real-world use.
"Achieving both UL and CSA certifications for our Breath Collection Unit is a major milestone for Cannabix that reflects our focus on product safety, quality, and regulatory compliance as we continue positioning our technology during phased commercial deployment." Stated, Rav Mlait, CEO Cannabix Technologies Inc.
Positioning for Future GrowthAs regulatory scrutiny and demand increase for non-invasive, recent-use marijuana screening solutions, The Company believes that compliance with recognized international safety standards will be an important enabler for scaling adoption. The Company expects these certifications to support ongoing discussions with government agencies, employers, and strategic partners seeking compliant and reliable testing solutions.
The Marijuana Breath Test (MBT) incorporates Cannabix's proprietary Breath Collection Unit and Breath Cartridge technologies, designed to collect and preserve breath samples for analysis using gold-standard liquid chromatography-mass spectrometry (LC-MS) methods. Cannabix has a strategic partnership with Omega Laboratories Inc, a global leader in forensic drug testing for over 25 years. Omega holds multiple federal and international certifications and operates a world-class facility with extensive experience in novel drug detection technologies. Together, Cannabix and Omega are advancing the phased commercialization of the MBT system for customers in the U.S. and Canada.
Figure 2. Cannabix Marijuana Breath Test hardware with Breath Collection Unit (BCU) taking a breath sample.
About Cannabix Technologies Inc.Cannabix Technologies Inc. is a developer of marijuana and alcohol breath technologies for workplaces, law enforcement and other settings. Breath testing for delta-9 THC (the primary psychoactive ingredient in cannabis) focuses on recent marijuana use. Cannabix is the developer of the BreathLogix autonomous alcohol screening device for organizations who strive to improve alcohol safety and monitoringWe seek Safe Harbor. On behalf of the Board of Directors
"Rav Mlait"
CEOCannabix Technologies Inc.
For further information, contact the Company at info@cannabixtechnologies.com The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. Cautionary Statement Regarding Forward-Looking Statements
This news release contains certain "forward-looking statements" and "forward-looking information" within the meaning of applicable Canadian securities laws (collectively, "forward-looking statements"). All statements in this release that are not purely historical in nature should be considered forward-looking statements, including, without limitation, statements regarding: the Company's plans for the commercial rollout of the MBT system; anticipated customer adoption and market demand; expectations related to manufacturing scale-up, recurring revenue streams, and operational processes; potential technological developments or enhancements; future partnerships or commercial agreements; regulatory approvals; and the Company's ability to complete future financings or achieve other business milestones. Forward-looking statements are often identified by terminology such as "anticipate," "believe," "continue," "estimate," "expect," "goal," "intend," "may," "plan," "potential," "project," "proposed," "target," "will," and similar expressions, or statements that events or conditions "may" or "will" occur. These statements are based on the beliefs, assumptions, and expectations of management in light of currently available information. Forward-looking statements involve known and unknown risks, uncertainties, and other factors—many of which are beyond the Company's control—that may cause actual results, performance, or achievements to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to: adverse market conditions; the Company's ability to successfully manufacture, deploy, and commercialize the MBT system or any future products; risks associated with regulatory approvals and evolving legal frameworks for cannabis testing; reliance on third-party laboratory and manufacturing partners; the protection and enforceability of intellectual property rights; technological uncertainties; competition; potential delays in product development or customer adoption; risks related to future financings; and the possibility that strategic partnerships may not advance as expected or may not be completed at all. Readers are cautioned that undue reliance should not be placed on forward-looking statements. Actual results and future events may differ materially from those expressed or implied by such statements. Forward-looking statements in this release are provided as of the date hereof, and the Company undertakes no obligation to update or revise any forward-looking statements except as required under applicable securities laws.
Original: Cannabix Marijuana Breath Test Achieves Major Milestone: Breath Collection Unit Secures UL and CSA Certifications
CA Market News
2月前
Cannabix Technologies Announces Delivery of Marijuana Breath Test (MBT) to Virginia based Industrial Manufacturing ClientApril 1, 2026 8:50 AM
InvestorsHub NewsWire
Cannabix Technologies Announces Delivery of Marijuana Breath Test (MBT) to Virginia based Industrial Manufacturing Client Vancouver, British Columbia, April 1, 2026 -- Cannabix Technologies Inc. (CSE:BLO) (OTCID:BLOZF) (Frankfurt: 8CT) (the "Company" or "Cannabix") developer of marijuana and alcohol breath testing devices for workplace safety and law enforcement, is pleased to announce the commercial delivery of its Marijuana Breath Test ("MBT") products to a leading industrial manufacturing company with operations in the state of Virginia. The delivery was completed through an authorized reseller. The announcement highlights diverse industries that are adopting the Company's non-invasive breath-based testing products to support workplace safety programs. The client, which operates large-scale custom machinery fabrication, sought a scientifically grounded method to assess recent cannabis use among its workforce amid growing concerns about THC-related safety incidents and the limitations of traditional drug testing. Manufacturing Sector Faces Rising Cannabis-Related Safety PressuresIndustrial manufacturing environments—particularly those involving production lines, machining, robotics, welding, electrical systems, and material-handling equipment—are among the most safety-sensitive workplaces in the U.S. Employers across the sector report increasing challenges related to cannabis use, including:Higher rates of workplace injuries associated with safety-relevant reaction time and reduced situational awarenessLabor shortages, making it difficult to suspend or replace employees based solely on legacy drug testsOutdated testing methods (urine, saliva) that detect cannabis exposure from days or weeks priorLegal and policy conflicts resulting from state-level legalization of recreational and medical marijuanaInsurance and compliance pressures requiring clearer documentation of safety-relevant testing Manufacturing employers are especially impacted because they operate heavy equipment, must maintain strict safety programs, and cannot rely on drug tests that fail to distinguish recent cannabis use from historical use. MBT: A Modern, Non-invasive Tool for Detecting Recent Cannabis UseThe Cannabix MBT system is designed to detect delta-9 THC—the primary psychoactive compound in cannabis—in breath within four hours of use, at levels above 5 pg/L. This short detection window aligns closely with the period most correlated with recent-use effects, offering a valuable alternative to legacy drug tests that identify past consumption. The MBT includes Cannabix's proprietary Breath Collection Unit and Breath Cartridge technologies (see Figure 1) to collect and preserve breath samples for laboratory analysis using gold-standard liquid chromatography-mass spectrometry (LC-MS) methods. This window aligns closely with recent-use timeframes, offering an actionable alternative to legacy tests that detect past exposure. Figure 1. Cannabix Technologies Breath Collection Unit (BCU) "As industrial workplaces evolve and cannabis use becomes increasingly commonplace, manufacturers require tools that deliver fairness and scientific relevance," said Rav Mlait, CEO of Cannabix Technologies Inc. "Our early delivery of the MBT system to a major manufacturing client in Virginia demonstrates the growing interest for accurate, non-invasive testing that focuses specifically on recent cannabis use. This news highlights the MBT's readiness for deployment across high-risk industries that cannot compromise on safety." Strategic and Investor-Focused OutlookThis delivery marks another step in Cannabix's commercialization strategy, reinforcing the Company's competitive position within safety-sensitive industries. Industrial manufacturing represents a substantial near-term market opportunity due to:The sector's dependence on skilled labor operating high-risk equipmentIncreased THC-related incidents reported across U.S. manufacturing worksitesHeightened insurance requirements and safety auditsA shift toward recent-use testing tools rather than legacy exposure-based methods Cannabix is working to position the MBT as a new standard for detecting recent cannabis use across multiple safety-critical industries. The Company believes the MBT platform is well positioned to become a new standard for detecting recent cannabis use among employers with safety-critical operations. Cannabix maintains a strategic partnership with Omega Laboratories, Inc., a global leader in forensic drug testing for over 25 years, operating a fully accredited laboratory with extensive experience in novel drug-detection technologies. About Cannabix Technologies Inc.Cannabix Technologies Inc. is a developer of marijuana and alcohol breath technologies for workplaces, law enforcement and other settings. The Marijuana Breath Test (MBT) targets delta-9 THC (the primary psychoactive ingredient in cannabis) in breath and focuses on recent marijuana use. Cannabix is the developer of the BreathLogix autonomous alcohol screening device for organizations who strive to improve alcohol safety and monitoring. Visit www.cannabixtechnologies.com We seek Safe Harbor. On behalf of the Board of Directors "Rav Mlait" CEOCannabix Technologies Inc. For further information, contact the Company at info@cannabixtechnologies.com Cautionary Statement Regarding Forward-Looking Statements
This news release contains certain "forward-looking statements" and "forward-looking information" within the meaning of applicable Canadian securities laws (collectively, "forward-looking statements"). All statements in this release that are not purely historical in nature should be considered forward-looking statements, including, without limitation, statements regarding: the Company's plans for the commercial rollout of the MBT system; anticipated customer adoption and market demand; expectations related to manufacturing scale-up, recurring revenue streams, and operational processes; potential technological developments or enhancements; future partnerships or commercial agreements; regulatory approvals; and the Company's ability to complete future financings or achieve other business milestones. Forward-looking statements are often identified by terminology such as "anticipate," "believe," "continue," "estimate," "expect," "goal," "intend," "may," "plan," "potential," "project," "proposed," "target," "will," and similar expressions, or statements that events or conditions "may" or "will" occur. These statements are based on the beliefs, assumptions, and expectations of management in light of currently available information. Forward-looking statements involve known and unknown risks, uncertainties, and other factors—many of which are beyond the Company's control—that may cause actual results, performance, or achievements to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to: adverse market conditions; the Company's ability to successfully manufacture, deploy, and commercialize the MBT system or any future products; risks associated with regulatory approvals and evolving legal frameworks for cannabis testing; reliance on third-party laboratory and manufacturing partners; the protection and enforceability of intellectual property rights; technological uncertainties; competition; potential delays in product development or customer adoption; risks related to future financings; and the possibility that strategic partnerships may not advance as expected or may not be completed at all. Readers are cautioned that undue reliance should not be placed on forward-looking statements. Actual results and future events may differ materially from those expressed or implied by such statements. Forward-looking statements in this release are provided as of the date hereof, and the Company undertakes no obligation to update or revise any forward-looking statements except as required under applicable securities laws. The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.
Original: Cannabix Technologies Announces Delivery of Marijuana Breath Test (MBT) to Virginia based Industrial Manufacturing Client
CA Market News
3月前
Cannabix Technologies Announces First Delivery of Marijuana Breath Test (MBT) to a Major Construction ClientMarch 19, 2026 12:45 PM
InvestorsHub NewsWire
Cannabix Technologies Announces First Delivery of Marijuana Breath Test (MBT) to a Major Construction Client Vancouver, British Columbia, March 19, 2026 -- InvestorsHub NewsWire -- Cannabix Technologies Inc. (CSE:BLO) (OTCID:BLOZF) (Frankfurt: 8CT) (the "Company" or "Cannabix") developer of marijuana and alcohol breath testing devices for workplace safety and law enforcement, is pleased to announce the first commercial sales of its Marijuana Breath Test ("MBT") products into the construction industry. The products were sold to a major construction company located in the Pacific Northwest through an authorized reseller. The client—a large regional contractor engaged in industrial, civil, and commercial construction—sought a next-generation solution to strengthen workplace safety protocols by accurately assessing recent cannabis use among its workforce. A Critical Solution for Safety-Sensitive Industries The construction sector faces one of the highest incidences of workplace injuries among all U.S. industries, which may be exacerbated by rising cannabis use. Safety-sensitive environments such as active job sites, heavy equipment operations, and high-risk trades require tools that help employers distinguish recent cannabis use from historical, leisure time use. Traditional drug testing technologies—urine, saliva, and hair—are fundamentally limited:They detect past use, not recent use, often identifying cannabis consumption days or weeks old.They offer limited correlation to impairment-relevant timeframes, reducing their usefulness for active duty safety decisions.They create legal and labor-relations challenges in states with legalized recreational and medical cannabis, where employees may test positive despite off-duty, lawful use. Sectors such as construction, transportation, logistics, warehousing, and manufacturing are disproportionately affected because they operate under strict safety requirements and face persistent labor shortages. Employers in these industries are urgently seeking fair, modern, and defensible methods for managing cannabis risk without penalizing employees for lawful off-duty behavior. MBT: Purpose-Built for Recent Use DetectionThe Cannabix MBT directly addresses this longstanding gap. It detects delta-9 THC—the primary psychoactive component of cannabis—in breath within approximately four hours of use at levels above 5 pg/L. The MBT incorporates Cannabix's proprietary Breath Collection Unit and Breath Cartridge technologies (see Figure 1) to collect and preserve breath samples for laboratory analysis using gold-standard liquid chromatography-mass spectrometry (LC-MS) methods. This window aligns closely with impairment-relevant timeframes, offering an actionable alternative to legacy tests that detect past exposure. Figure 1. Cannabix Marijuana Breath Test hardware with Breath Collection Unit (BCU) taking a breath sample. The MBT includes:Cannabix Breath Collection Unit (BCU)Single-use, disposable Breath CartridgesThe Laboratory Developed Test (LDT) Method by Omega Laboratories Cannabix maintains a strategic partnership with Omega Laboratories Inc., a global leader in forensic drug testing for more than 25 years, operating a world-class accredited laboratory with extensive expertise in novel detection technologies. "As cannabis use continues to expand across the United States, safety-sensitive industries are struggling with outdated drug testing methods that do not reflect real-world workplace needs," said Rav Mlait, CEO of Cannabix Technologies Inc. "Our Marijuana Breath Test provides a modern, scientifically grounded way to identify recent cannabis use in a fair and non-invasive manner. This first commercial delivery to a major construction contractor is an important milestone that supports safer operations and more informed decision-making." Investor-Focused OutlookThis initial commercial delivery represents a key advancement in Cannabix's commercialization strategy. The Company anticipates increasing interest from large employers facing regulatory pressure, growing insurance requirements, and operational demands for more precise impairment-related testing. Construction and industrial sectors—characterized by high workforce volumes and strict safety mandates—represent near-term market opportunities. The Company continues to work with its resellers and advance production capabilities for the MBT. Cannabix is working to position the MBT as a new standard for detecting recent cannabis use across multiple safety-critical industries. Scientific research shows that delta-9 THC is detectable in breath for a short window of approximately 2–4 hours, closely aligned with the period of peak impairment. Breath analysis provides the easiest, most relevant and scientifically meaningful indication of recent use, which is the metric employers and safety-sensitive industries require. About Cannabix Technologies Inc.Cannabix Technologies Inc. is a developer of marijuana and alcohol breath technologies for workplaces, law enforcement and other settings. The Marijuana Breath Test (MBT) targets delta-9 THC (the primary psychoactive ingredient in cannabis) in breath and focuses on recent marijuana use. Cannabix is the developer of the BreathLogix autonomous alcohol screening device for organizations who strive to improve alcohol safety and monitoring. Visit www.cannabixtechnologies.com We seek Safe Harbor. On behalf of the Board of Directors "Rav Mlait" CEOCannabix Technologies Inc. For further information, contact the Company at info@cannabixtechnologies.com Cautionary Statement Regarding Forward-Looking Statements
This news release contains certain "forward-looking statements" and "forward-looking information" within the meaning of applicable Canadian securities laws (collectively, "forward-looking statements"). All statements in this release that are not purely historical in nature should be considered forward-looking statements, including, without limitation, statements regarding: the Company's plans for the commercial rollout of the MBT; anticipated customer adoption and market demand; expectations related to manufacturing scale-up, recurring revenue streams, and operational processes; potential technological developments or enhancements; future partnerships or commercial agreements; regulatory approvals; and the Company's ability to complete future financings or achieve other business milestones. Forward-looking statements are often identified by terminology such as "anticipate," "believe," "continue," "estimate," "expect," "goal," "intend," "may," "plan," "potential," "project," "proposed," "target," "will," and similar expressions, or statements that events or conditions "may" or "will" occur. These statements are based on the beliefs, assumptions, and expectations of management in light of currently available information. Forward-looking statements involve known and unknown risks, uncertainties, and other factors—many of which are beyond the Company's control—that may cause actual results, performance, or achievements to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to: adverse market conditions; the Company's ability to successfully manufacture, deploy, and commercialize the MBT or any future products; risks associated with regulatory approvals and evolving legal frameworks for cannabis testing; reliance on third-party laboratory and manufacturing partners; the protection and enforceability of intellectual property rights; technological uncertainties; competition; potential delays in product development or customer adoption; risks related to future financings; and the possibility that strategic partnerships may not advance as expected or may not be completed at all. Readers are cautioned that undue reliance should not be placed on forward-looking statements. Actual results and future events may differ materially from those expressed or implied by such statements. Forward-looking statements in this release are provided as of the date hereof, and the Company undertakes no obligation to update or revise any forward-looking statements except as required under applicable securities laws. The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.
Original: Cannabix Technologies Announces First Delivery of Marijuana Breath Test (MBT) to a Major Construction Client
CA Market News
3月前
Cannabix Technologies Announces Commercial Launch of Marijuana Breath Test (MBT)March 16, 2026 8:37 AM
InvestorsHub NewsWire
Cannabix Technologies Announces Commercial Launch of Marijuana Breath Test (MBT) Vancouver, British Columbia, March 16, 2026 -- Cannabix Technologies Inc. (CSE:BLO) (OTCID:BLOZF) (Frankfurt: 8CT) (the "Company" or "Cannabix") is pleased to announce the commencement of its commercial phased rollout of the Marijuana Breath Test ("MBT") system. This phase includes the delivery of MBT units to select commercial customers across multiple industries, followed by a planned scale-up in production. The Marijuana Breath Test fills a critical gap and delivers new technology and methods that provide a complete, non-invasive solution for detecting recent cannabis use, specifically delta-9 THC (the primary psychoactive compound in cannabis) in breath, within approximately 4 hours of consumption at levels above 5 pg/L. This capability addresses a long-standing need among employers, law enforcement agencies, and safety-sensitive industries, which have historically relied on testing methods that detect primarily past cannabis use. As legalized recreational and medical marijuana use continues to expand across the United States and globally, accurate detection of recent use via breath is becoming essential for maintaining fairness, relevance, and informed decision-making. See product video link: https://cannabixtechnologies.com/products/cannabix-marijuana-breath-test/ Figure 1. Cannabix Marijuana Breath Test hardware including Breath Collection Unit (BCU) and Breath Cartridge (BC) technologies. In early March 2026, an independent peer-reviewed publication in the Journal of Analytical Toxicology (JAT) became publicly available confirming the ability of the MBT system to detect delta-9 THC. Over recent months, Cannabix and its partners have completed many initiatives to enable the commercial rollout of the MBT system:Key enhancements to the Breath Collection Unit (BCU) and Breath Cartridges (Figures 1 and 2), along with the initial validation package prepared by Omega Laboratories ("Omega").Integration of Cannabix Breath Cartridges into Omega's operational workflows, including chain-of-custody processes and electronic reporting through its Laboratory Information Management System (LIMS).Established manufacturing procedures and partnerships, standard operating procedures, and QA/QC processes for MBT hardware.BCU successfully passing FCC electronic emissions testing.The MBT system will follow a recurring revenue model in which the handheld BCU serves as the required hardware for all deployments, while disposable Breath Cartridges generate ongoing revenue as they are used for every test performed. Pre-launch marketing initiatives conducted with Omega (Ohio) and AlcoPro (Knoxville, TN).Preparation of end-user training materials, logistics planning, and customer support resources.Release of peer-reviewed Journal of Analytical Toxicology publication, titled: "Simultaneous Analysis of ?9-THC, ?8-THC, CBD, and CBN in Breath Aerosols Collected Using Cannabix Technologies Breath Collection Unit." (March 2026) link: https://doi.org/10.1093/jat/bkag016 The MBT platform consists of the Cannabix Breath Collection Unit (BCU), disposable Breath Cartridges, and the Laboratory-Developed Test Method by Omega Laboratories. Cannabix has a strategic partnership with Omega Laboratories Inc, a global leader in forensic drug testing for over 25 years. Omega holds multiple federal and international certifications and operates a world-class facility with extensive experience in novel drug detection technologies. Why Recent Use Detection of Cannabis Is ImportantTraditional cannabis testing methods such as urine, saliva, or hair analysis, primarily detect historical cannabis use. These methods can return positive results hours, days, or even weeks after consumption, making them ineffective for determining whether an individual may be using during the workday. Figure 2. Cannabix Marijuana Breath Test hardware with Breath Collection Unit (BCU) taking a breath sample. Scientific research shows that delta-9 THC is detectable in breath for a short window of approximately 2–4 hours, closely aligned with the period of peak impairment. Breath analysis therefore provides the most relevant and scientifically meaningful indication of recent use, which is the metric employers and safety-sensitive industries require. About Cannabix Technologies Inc.Cannabix Technologies Inc. is a developer of marijuana and alcohol breath technologies for workplaces, law enforcement and other settings. The Marijuana Breath Test (MBT) targets delta-9 THC (the primary psychoactive ingredient in cannabis) in breath and focuses on recent marijuana use. Cannabix is the developer of the BreathLogix autonomous alcohol screening device for organizations who strive to improve alcohol safety and monitoring. Visit www.cannabixtechnologies.com We seek Safe Harbor. On behalf of the Board of Directors "Rav Mlait" CEOCannabix Technologies Inc. For further information, contact the Company at info@cannabixtechnologies.com Cautionary Statement Regarding Forward-Looking Statements
This news release contains certain "forward-looking statements" and "forward-looking information" within the meaning of applicable Canadian securities laws (collectively, "forward-looking statements"). All statements in this release that are not purely historical in nature should be considered forward-looking statements, including, without limitation, statements regarding: the Company's plans for commercial rollout of the MBT system; anticipated customer adoption and market demand; expectations regarding manufacturing scale-up, recurring revenue streams, and operational processes; potential technological developments or enhancements; future partnerships or commercial agreements; regulatory approvals; and the Company's ability to complete future financings or achieve other business milestones. Forward-looking statements are often identified by terminology such as "anticipate," "believe," "continue," "estimate," "expect," "goal," "intend," "may," "plan," "potential," "project," "proposed," "target," "will," and similar expressions, or statements that events or conditions "may" or "will" occur. These statements are based on the beliefs, assumptions, and expectations of management in light of currently available information. Forward-looking statements involve known and unknown risks, uncertainties, and other factors—many of which are beyond the Company's control—that may cause actual results, performance, or achievements to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to: adverse market conditions; the ability of the Company to successfully manufacture, deploy, and commercialize the MBT system or any future products; risks related to regulatory approvals and evolving legal frameworks for cannabis testing; reliance on third-party laboratory partnerships and manufacturing partners; the protection and enforceability of intellectual property rights; technological uncertainties; competition; potential delays in product development or customer adoption; risks associated with future financings; and the possibility that strategic partnerships may not advance as expected or may not be completed at all. Readers are cautioned that undue reliance should not be placed on forward-looking statements. Actual results and future events may differ materially from those expressed or implied by such statements. Forward-looking statements in this release are provided as of the date hereof, and the Company undertakes no obligation to update or revise any forward-looking statements except as required under applicable securities laws. The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.
Original: Cannabix Technologies Announces Commercial Launch of Marijuana Breath Test (MBT)
CA Market News
3月前
Journal of Analytical Toxicology Publishes Peer-Reviewed Validation StudyMarch 3, 2026 8:18 AM
InvestorsHub NewsWire
Journal of Analytical Toxicology Publishes Peer-Reviewed Validation Study Demonstrating Accuracy of Omega Laboratories' Test Method for Detecting Marijuana in Breath Samples Using Cannabix Technologies' Breath Collection UnitVancouver, British Columbia, March 3, 2026 -- Cannabix Technologies Inc. (CSE:BLO) (OTCID:BLOZF) (Frankfurt: 8CT) (the "Company" or "Cannabix") and Omega Laboratories Inc ("Omega") proudly announce the peer-reviewed publication of a groundbreaking study published by Oxford University Press in the prestigious Journal of Analytical Toxicology titled: "Simultaneous Analysis of ?9-THC, ?8-THC, CBD, and CBN in Breath Aerosols Collected Using Cannabix Technologies Breath Collection Unit." This marks a major milestone in the advancement of marijuana breath testing technology globally. The study demonstrates the accuracy and utility of Omega Laboratories' analytical method for detecting cannabinoids in breath samples collected using Cannabix Technologies' Breath Collection Unit and Breath Cartridges—further validating the system as the leading solution for identifying recent marijuana use. For employers, law enforcement agencies, and safety-sensitive industries, this breath-based testing system offers a reliable, non-invasive solution for detecting recent cannabis consumption. This capability fills a critical gap left by traditional methods, which often detect historical—rather than recent—use. In May of 2024 Omega and Cannabix entered a strategic partnership to accelerate design improvements on the Cannabix Breath Collection Unit (BCU) as well as the laboratory test method. Over the course of 20 months, Cannabix made several key enhancements to the BCU while Omega refined the analytical methodology to test breath for usage of marijuana. These successful efforts were combined into the validation study recently published by the Journal of Analytical Toxicology, which is available here: https://doi.org/10.1093/jat/bkag016Cannabix Marijuana Breath Test hardware including Breath Collection Unit (BCU) and Breath Cartridge (BC) technologies. With medical and recreational marijuana use expanding, identification of recent cannabis use whether via smoking or ingestion has become more critical than ever for workplace drug testing, drug treatment facilities, and road safety programs. Detection of recent cannabis use in exhaled breath offers an alternative to the more invasive and intrusive testing methods using blood or urine. Breath testing, long established for alcohol detection, has recently gained attention for drug testing following evidence that multiple substances can be identified in breath after consumption. The detection window in breath correlates with those found in blood and can assist with the identification of recency of use within the last 4 hours prior to collection. While alcohol breathalyzers are long-established, cannabis testing remains scientifically complex because THC levels in breath are extremely low. Omega has refined precision testing at these low levels for decades by being experts in utilizing hair samples to detect long-term drug usage. Omega's laboratory validated method combined with the Cannabix Breath Collection Unit has created the most commercially viable, non-invasive system for identifying same-day THC usage. Publication in the Journal of Analytical Toxicology (JAT) indicates the research on the identification and measurement of toxic substances in biological samples has passed rigorous peer review. It adds to the body of knowledge for the toxicology community. JAT is the official journal of the Society of Forensic Toxicologists (SOFT) and The International Association of Forensic Toxicologists (TIAFT). The method was validated according to ANSI/ASB Standard 036, First Edition 2019 guidelines. "This new publication reinforces the effectiveness of using breath to detect recent drug use," said Bill Corl, CEO of Omega. "This achievement further demonstrates our expertise in forensic toxicology and our commitment to providing advanced testing solutions."Omega's method validation builds upon dozens of previously published papers while introducing several new key findings. These include:The ability to simultaneously quantify multiple cannabinoids via breath aerosols including ?9- tetrahydrocannabinol (?9-THC), ?8-tetrahydrocannabinol (?8-THC), cannabidiol (CBD), and cannabinol (CBN).The validation of a robust laboratory method that is quicker and simpler than previous approaches while achieving improved detection sensitivity and precision. The establishment of breath sample stability for up to 7 days via the Cannabix Breath Collection Kit.Further confirmation that the concentration versus time trends for THC metabolism assessed from breath correlate with those previously reported from blood.Due to testing complexity requiring the use of LC-MS/MS, analysis must be performed in a laboratory. Collections performed at the roadside, workplace or in a clinic environment are sent to the laboratory and tested to see if a person had consumed marijuana 15 minutes to 4 hours prior to an incident. This is a very important tool that can be used in combination with other evidence for roadside and other safety sensitive investigations. The breath collection process includes an ambient air sample followed by an A & B sample which are collected simultaneously with the use of the Cannabix collection cartridge. Omega screens the A sample using LC-MS/MS then, if presumptively positive, the B sample is also tested using LC-MS/MS. If both samples are positive the ambient air sample is tested to rule-out environmental contamination. Rav Mlait, CEO of Cannabix Technologies, stated, "The peer-reviewed article publication in the prestigious Journal of Analytical Toxicology is a significant milestone for Cannabix and its shareholders. I commend the dedicated efforts of both the Cannabix and Omega teams in advancing our breath-based technology to help improve public safety."Cannabix is currently working to ramp up manufacturing of the BCU's and Breath Collection Kits. The Cannabix BCU brings several advantages:Omega's validation helps establish the Cannabix BCU as a stable, consistent and portable tool for breath collection. The BCU offers a quick, non-invasive collection method regardless of subject's lung function.The BCU adds several safeguards to the reproducible collection process, including the monitoring of subject's breath pressure and volume, the ability to collect ambient air for specimen validity, and A & B cartridges for a dual testing process.The Breath Collection Kit cartridges used by the BCU are currently the most robust method of sending breath samples for laboratory testing. The sturdy nature of the cartridges combined with shipping stability time helps ensure that samples can be successfully processed once received at Omega Laboratories.The teams at Omega Laboratories and Cannabix are pleased to partner together so that this innovative, much-needed technology is available for safety-sensitive applications.Marketing Agreement ExtensionEffective March 3, 2026, the Company has extended an arm's length marketing agreement with Black Swan Solutions Inc. dba VHLA Media to provide certain digital marketing services ("Services") to the company, including development of social media content and a marketing campaign distributed through online platforms. The Engagement is for a term of one month and may be renewed or extended for subsequent periods if mutually agreed upon by VHLA and the Company. As consideration for the engagement, the company will pay VHLA a fee of US$8,000. The Company will not issue any securities to VHLA Media as compensation for its Services. As of the date hereof, to the Company's knowledge, VHLA Media does not own any securities of the Company. VHLA Media contact information, Dawson Ignatieff, 604-762-1611, contact@vhlamedia.com. We seek Safe Harbor. On behalf of the Board of Directors "Rav Mlait" CEOCannabix Technologies Inc. For further information, contact the Company at info@cannabixtechnologies.comAbout Cannabix Technologies Inc - Cannabix Technologies Inc. (CSE: BLO) (OTCID: BLOZF) is a developer of marijuana and alcohol breath technologies for workplaces, law enforcement and other settings. The Marijuana Breath Test (MBT) targets delta-9 THC (the primary psychoactive ingredient in cannabis) in breath and focuses on recent marijuana use. Cannabix is the developer of the BreathLogix autonomous alcohol screening device for organizations who strive to improve alcohol safety and monitoring. www.cannabixtechnologies.comAbout Omega Laboratories, Inc. - Omega Laboratories, Inc. headquartered in Mogadore, Ohio with an additional state-of-the-art facility in Ontario, Canada provides laboratory-based advanced testing solutions to over 6,000 clients worldwide. Omega Laboratories has over 25 years of experience in pioneering innovative drug testing methodologies, specializing in the detection of drugs of abuse utilizing Hair, Oral Fluid, Urine and Breath specimens. Omega continues to innovate with the launch of their Technical Solutions portfolio that incorporates a paperless Custody & Control Form system (oCCF) in sixteen languages, Software as a Service (SaaS) of a Laboratory Information Management System (LIMS) designed specifically for Toxicology and powers laboratories in countries that have demand for local service providers. www.omegalaboratories.comThe Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. Cautionary Statement Regarding Forward-Looking Statements
This news release contains forward-looking statements within the meaning of applicable securities laws. Forward-looking statements are often identified by terms such as "anticipates," "expects," "intends," "believes," "estimates," "may," "will," "potential," "proposed," "positioned," and similar expressions, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements in this release include, but are not limited to: statements regarding the interpretation, impact, and potential use of the peer-reviewed study; the performance, capabilities, and advantages of the Cannabix Breath Collection Unit and Breath Collection Kits; anticipated demand for breath-based cannabis testing; the scalability and manufacturing of devices and cartridges; the development, validation, and commercialization of technologies described; the potential adoption of breath testing by workplace, forensic, clinical, or law enforcement customers; expectations regarding additional testing, pilot programs, or regulatory processes; and the growth of market opportunities related to cannabis impairment detection. Forward-looking statements involve numerous risks and uncertainties that may cause actual results, performance, or achievements to differ materially from those expressed or implied in the statements. Such risks include, but are not limited to: the risk that scientific results, including validation or peer-review findings, may not be replicated in broader use; that further research or regulatory review may require changes to testing methods or device design; risks associated with product development, manufacturing scale-up, supply chain availability, or cost escalation; risks relating to commercialization, customer adoption, and market acceptance of new testing technologies; the ability of the Company and its partners to meet regulatory, forensic, or evidentiary standards; risks associated with intellectual property protection and patent approvals; competitive technologies or market changes; general economic, financial, or operational risks; and risks that expected agreements, partnerships, or deployments may not materialize or may be delayed. There is no assurance that any proposed products will be successfully developed, manufactured at scale, validated by regulators or customers, or achieve commercial adoption. There is no assurance that breath-based THC detection will be accepted as a legal standard or evidentiary tool in any jurisdiction, or that peer-review publication will result in commercial, regulatory, or legal benefits. Actual results and future events may differ materially from those anticipated. All forward-looking statements in this release are made as of the date hereof and are based on current expectations, estimates, and assumptions that involve significant business, scientific, regulatory, and economic uncertainties. The Company undertakes no obligation to update forward-looking statements except as required by law.
Original: Journal of Analytical Toxicology Publishes Peer-Reviewed Validation Study
CA Market News
3月前
Journal of Analytical Toxicology Publishes Peer-Reviewed Validation Study Demonstrating Accuracy of Omega Laboratories' Test Method for Detecting Marijuana in Breath Samples Using Cannabix Technologies' Breath Collection UnitMarch 3, 2026 8:10 AM
PR Newswire (Canada)
MOGADORE, Ohio and VANCOUVER, BC, March 3, 2026 /CNW/ -- Omega Laboratories, Inc. and Cannabix Technologies Inc. (CSE: BLO) (OTCID: BLOZF) proudly announce the peer-reviewed publication of a groundbreaking study published by Oxford University Press in the prestigious Journal of Analytical Toxicology titled: "Simultaneous Analysis of ?9-THC, ?8-THC, CBD, and CBN in Breath Aerosols Collected Using Cannabix Technologies Breath Collection Unit." This marks a major milestone in the advancement of marijuana breath testing technology globally.
The study demonstrates the accuracy and utility of Omega Laboratories' analytical method for detecting cannabinoids in breath samples collected using Cannabix Technologies' Breath Collection Unit and Breath Cartridges—further validating the system as the leading solution for identifying recent marijuana use. For employers, law enforcement agencies, and safety-sensitive industries, this breath-based testing system offers a reliable, non-invasive solution for detecting recent cannabis consumption. This capability fills a critical gap left by traditional methods, which often detect historical—rather than recent—use.In May of 2024 Omega and Cannabix entered a strategic partnership to accelerate design improvements on the Cannabix Breath Collection Unit (BCU) as well as the laboratory test method. Over the course of 20 months, Cannabix made several key enhancements to the BCU while Omega refined the analytical methodology to test breath for usage of marijuana. These successful efforts were combined into the validation study recently published by the Journal of Analytical Toxicology, which is available here: https://doi.org/10.1093/jat/bkag016With medical and recreational marijuana use expanding, identification of recent cannabis use whether via smoking or ingestion has become more critical than ever for workplace drug testing, drug treatment facilities, and road safety programs. Detection of recent cannabis use in exhaled breath offers an alternative to the more invasive and intrusive testing methods using blood or urine. Breath testing, long established for alcohol detection, has recently gained attention for drug testing following evidence that multiple substances can be identified in breath after consumption. The detection window in breath correlates with those found in blood and can assist with the identification of recency of use within the last 4 hours prior to collection.While alcohol breathalyzers are long-established, cannabis testing remains scientifically complex because THC levels in breath are extremely low. Omega has refined precision testing at these low levels for decades by being experts in utilizing hair samples to detect long-term drug usage. Omega's laboratory validated method combined with the Cannabix Breath Collection Unit has created the most commercially viable, non-invasive system for identifying same-day THC usage.Publication in the Journal of Analytical Toxicology (JAT) indicates the research on the identification and measurement of toxic substances in biological samples has passed rigorous peer review. It adds to the body of knowledge for the toxicology community. JAT is the official journal of the Society of Forensic Toxicologists (SOFT) and The International Association of Forensic Toxicologists (TIAFT). The method was validated according to ANSI/ASB Standard 036, First Edition 2019 guidelines."This new publication reinforces the effectiveness of using breath to detect recent drug use," said Bill Corl, CEO of Omega. "This achievement further demonstrates our expertise in forensic toxicology and our commitment to providing advanced testing solutions."Omega's method validation builds upon dozens of previously published papers while introducing several new key findings. These include:The ability to simultaneously quantify multiple cannabinoids via breath aerosols including ?9- tetrahydrocannabinol (?9-THC), ?8-tetrahydrocannabinol (?8-THC), cannabidiol (CBD), and cannabinol (CBN).The validation of a robust laboratory method that is quicker and simpler than previous approaches while achieving improved detection sensitivity and precision. The establishment of breath sample stability for up to 7 days via the Cannabix Breath Collection Kit.Further confirmation that the concentration versus time trends for THC metabolism assessed from breath correlate with those previously reported from blood.Due to testing complexity requiring the use of LC-MS/MS, analysis must be performed in a laboratory. Collections performed at the roadside, workplace or in a clinic environment are sent to the laboratory and tested to see if a person had consumed marijuana 15 minutes to 4 hours prior to an incident. This is a very important tool that can be used in combination with other evidence for roadside and other safety sensitive investigations.The breath collection process includes an ambient air sample followed by an A & B sample which are collected simultaneously with the use of the Cannabix collection cartridge. Omega screens the A sample using LC-MS/MS then, if presumptively positive, the B sample is also tested using LC-MS/MS. If both samples are positive the ambient air sample is tested to rule-out environmental contamination.Rav Mlait, CEO of Cannabix Technologies, stated, "The peer-reviewed article publication in the prestigious Journal of Analytical Toxicology is a significant milestone for Cannabix and its shareholders. I commend the dedicated efforts of both the Cannabix and Omega teams in advancing our breath-based technology to help improve public safety."Cannabix is currently working to ramp up manufacturing of the BCU's and Breath Collection Kits. The Cannabix BCU brings several advantages:Omega's validation helps establish the Cannabix BCU as a stable, consistent and portable tool for breath collection. The BCU offers a quick, non-invasive collection method regardless of subject's lung function.The BCU adds several safeguards to the reproducible collection process, including the monitoring of subject's breath pressure and volume, the ability to collect ambient air for specimen validity, and A & B cartridges for a dual testing process.The Breath Collection Kit cartridges used by the BCU are currently the most robust method of sending breath samples for laboratory testing. The sturdy nature of the cartridges combined with shipping stability time helps ensure that samples can be successfully processed once received at Omega Laboratories.The teams at Omega Laboratories and Cannabix are pleased to partner together so that this innovative, much-needed technology is available for safety-sensitive applications.For additional information on these solutions, please contact Omega at 1-800-665-5569 or sales@omegalabs.net.About Omega Laboratories, Inc. – Omega Laboratories, Inc. headquartered in Mogadore, Ohio with an additional state-of-the-art facility in Ontario, Canada provides laboratory-based advanced testing solutions to over 6,000 clients worldwide. Omega Laboratories has over 25 years of experience in pioneering innovative drug testing methodologies, specializing in the detection of drugs of abuse utilizing Hair, Oral Fluid, Urine and Breath specimens. Omega continues to innovate with the launch of their Technical Solutions portfolio that incorporates a paperless Custody & Control Form system (oCCF) in sixteen languages, Software as a Service (SaaS) of a Laboratory Information Management System (LIMS) designed specifically for Toxicology and powers laboratories in countries that have demand for local service providers. www.omegalaboratories.comAbout Cannabix Technologies Inc – Cannabix Technologies Inc. (CSE: BLO) (OTCID: BLOZF) is a developer of marijuana and alcohol breath technologies for workplaces, law enforcement and other settings. The Marijuana Breath Test (MBT) targets delta-9 THC (the primary psychoactive ingredient in cannabis) in breath and focuses on recent marijuana use. Cannabix is the developer of the BreathLogix autonomous alcohol screening device for organizations who strive to improve alcohol safety and monitoring. www.cannabixtechnologies.comFor further information, contact Cannabix Technologies Inc. at info@cannabixtechnologies.comThe Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.Cautionary Statement Regarding Forward-Looking Statements
This news release contains forward-looking statements within the meaning of applicable securities laws. Forward-looking statements are often identified by terms such as "anticipates," "expects," "intends," "believes," "estimates," "may," "will," "potential," "proposed," "positioned," and similar expressions, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements in this release include, but are not limited to: statements regarding the interpretation, impact, and potential use of the peer-reviewed study; the performance, capabilities, and advantages of the Cannabix Breath Collection Unit and Breath Collection Kits; anticipated demand for breath-based cannabis testing; the scalability and manufacturing of devices and cartridges; the development, validation, and commercialization of technologies described; the potential adoption of breath testing by workplace, forensic, clinical, or law enforcement customers; expectations regarding additional testing, pilot programs, or regulatory processes; and the growth of market opportunities related to cannabis impairment detection. Forward-looking statements involve numerous risks and uncertainties that may cause actual results, performance, or achievements to differ materially from those expressed or implied in the statements. Such risks include, but are not limited to: the risk that scientific results, including validation or peer-review findings, may not be replicated in broader use; that further research or regulatory review may require changes to testing methods or device design; risks associated with product development, manufacturing scale-up, supply chain availability, or cost escalation; risks relating to commercialization, customer adoption, and market acceptance of new testing technologies; the ability of the Company and its partners to meet regulatory, forensic, or evidentiary standards; risks associated with intellectual property protection and patent approvals; competitive technologies or market changes; general economic, financial, or operational risks; and risks that expected agreements, partnerships, or deployments may not materialize or may be delayed. There is no assurance that any proposed products will be successfully developed, manufactured at scale, validated by regulators or customers, or achieve commercial adoption. There is no assurance that breath-based THC detection will be accepted as a legal standard or evidentiary tool in any jurisdiction, or that peer-review publication will result in commercial, regulatory, or legal benefits. Actual results and future events may differ materially from those anticipated. All forward-looking statements in this release are made as of the date hereof and are based on current expectations, estimates, and assumptions that involve significant business, scientific, regulatory, and economic uncertainties. The Company undertakes no obligation to update forward-looking statements except as required by law.
View original content to download multimedia:https://www.prnewswire.com/news-releases/journal-of-analytical-toxicology-publishes-peerreviewed-validation-study-demonstrating-accuracy-of-omega-laboratories-test-method-for-detecting-marijuana-in-breath-samples-using-cannabix-technologies-breath-collection-unit-302701736.htmlSOURCE Omega Laboratories, Inc.
Original: Journal of Analytical Toxicology Publishes Peer-Reviewed Validation Study Demonstrating Accuracy of Omega Laboratories' Test Method for Detecting Marijuana in Breath Samples Using Cannabix Technologies' Breath Collection Unit
Hot Features
プレミアム
登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
shell3
1月前
High420
4年前
abazaba375
8年前
JosiePicks
9年前
メールアドレスで登録
